

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

CT (LUX) AMERICAN EXTENDED ALPHA (THE "FUND")

Class ZU (USD Accumulation Shares) LU1864950396, a sub-fund of Columbia Threadneedle (Lux) I (the "SICAV"), regulated by the CSSF.

The management company of the SICAV is Threadneedle Management Luxembourg S.A. (the "Management Company") (part of the Columbia and Threadneedle group of companies).

Objectives and Investment Policy

- The Fund aims to increase the value of your investment over the long term.
- At least two-thirds of the Fund's assets will be in long and short positions in companies in North America or companies that have significant operations there.
- The Fund invests directly in shares or by using derivatives (complex instruments). Derivatives will be used to obtain, increase or reduce exposure to underlying assets and may create leverage. Where leverage is created, the net asset value of the Fund may experience more fluctuation than if there were no leverage. The Fund will also use derivatives for short selling (which is designed to make a profit from falling prices), hedging purposes or to manage the Fund more efficiently.
- The Fund may also invest in asset classes and instruments different from those stated above.
- The Fund is actively managed in reference to the S&P 500 Index. The index is broadly representative of the companies in which the Fund invests, and provides a suitable target benchmark against which Fund performance will be measured and evaluated over time. The fund manager has discretion to select investments with weightings different to the index, and that are not in the index, and the Fund may display significant divergence from the index.
- Income from investments in the Fund will be added to the value of your shares.
- You can buy or sell shares in the Fund on any day which is a business day in Luxembourg unless the directors have decided that insufficient markets are open. You can find more detail on the investment objective and policy of the Fund in the Prospectus. For more information on investment terms used in this document, please see the Glossary available at columbiathreadneedle.com.
- Recommendation: this fund may not be appropriate for investors who plan to withdraw their money within 5 years.

Risk and Reward Profile

The Risk and Reward Indicator table demonstrates where the Fund ranks in terms of its potential risk and reward. The higher the rank the greater the potential reward but the greater the risk of losing money. It is based on past data, may change over time and may not be a reliable indication of the future risk profile of the Fund. The shaded area in the table below shows the Fund's ranking on the Risk and Reward Indicator.

Lower Risk,
Typically lower rewards

Higher Risk,
Typically higher rewards



- The Fund is rated 6 based on the Fund's risk limit which indicates that it may show a high level of volatility (how much the value of the Fund goes up and down).
- The lowest category does not mean a risk-free investment.
- The value of investments can fall as well as rise and investors might not get back the sum originally invested.
- Where investments are in assets that are denominated in multiple currencies, or currencies other than your own, changes in exchange rates may affect the value of the investments.
- The Fund may enter into financial transactions with selected counterparties. Any financial difficulties arising at these counterparties could significantly affect the availability and the value of Fund assets.
- The Fund's assets may sometimes be difficult to value objectively and the actual value may not be recognised until assets are sold.
- The Fund may invest materially in derivatives (complex instruments linked to the rise and fall of the value of other assets). A relatively small change in the value of the underlying investment may have a much larger positive or negative impact on the value of the derivative.
- Leverage occurs when economic exposure through derivatives is greater than the amount invested. Such exposure, and the use of short selling techniques, may lead to the Fund suffering losses in excess of the amount it initially invested.
- The risks currently identified as applying to the Fund are set out in the "Risk Factors" section of the Prospectus.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest

Entry Charge:	5.00%
Exit Charge:	0.00%

These are the maximum charges that we might take out of your money before it is invested. In some cases, you might pay less and you should speak to your financial adviser about this.

Charges taken from the fund over a year

Ongoing Charges:	1.05%
------------------	-------

Charges taken from the fund under certain specific conditions


Performance Fee:	NONE
------------------	------

Switching charge (for switching into the Fund from another fund) 0.75%

The ongoing charges figure is based on expenses for the year ending 31/03/24. It excludes the costs of buying or selling assets for the Fund (unless these assets are shares of another fund).

For more information about charges please see the Fund's prospectus.

Past Performance



Source: Morningstar

Past performance is not a guide to future performance.

Fund launch date: 25/01/2019

Share/unit class launch date: 25/01/2019

Performance is calculated in USD.

All charges and fees, except any entry, exit and switching charge, have been included within the performance.

This chart shows how much the Fund increased or decreased in value as a percentage each year.

*S&P 500 (Although the Fund makes reference to the index as part of the investment process, it is not intended that the performance of the Fund should track the index.)

The past performance information for the period prior to 25 January 2019 is from the CT American Extended Alpha Fund (Class 1 Accumulation Shares (USD) GB00B28CMR29) (a UK authorised UK UCITS fund launched on 22 October 2007), which merged into this Fund on 26 January 2019. The past performance calculated before 25 January 2019 includes UK taxes but does not include Luxembourg taxes.

Practical Information

- Depositary: Citibank Europe plc, Luxembourg branch.
- You can obtain further information about the Fund and the SICAV, its Prospectus, latest annual reports and any subsequent half-yearly reports free of charge from the Management Company. These documents are available in English, French, German, Portuguese (Prospectus only), Italian (Prospectus only), Spanish and Dutch (no Dutch Prospectus). You can obtain other practical information, including current share prices, at columbiathreadneedle.com.
- Details of the remuneration policy, including a description of how remuneration and benefits are calculated and the persons responsible for awarding them (including the composition of the remuneration committee), are available at columbiathreadneedle.com. A paper copy is available free of charge upon request.
- The tax legislation of Luxembourg may have an impact on your personal tax position.
- Threadneedle Management Luxembourg S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the UCITS.
- This document describes a single fund of the SICAV. The Prospectus and reports are prepared for the entire SICAV.
- The assets of the Fund are segregated by law and cannot be used to pay the liabilities of other funds of the SICAV.
- You may exchange your shares for shares of other funds of the SICAV, if available. Details can be found in the section of the Prospectus with the heading "Exchange Privilege". Details of other share classes of the Fund can be found in the Prospectus or at columbiathreadneedle.com.